OBJECTIVES: SUSTAINABILITY AND INNOVATION
The stated objective of the proposal is twofold: to make the regulatory process more predictable and, at the same time, sustainable for manufacturers—particularly small and medium-sized enterprises (SMEs). The current regulatory framework has often acted as a barrier, complicating market access for innovative technologies. With MDR 2.0, Europe aims to support innovation, ensuring that patients have rapid access to cutting-edge medical devices without compromising safety standards.
THE ROLLING REVIEW REVOLUTION
Among the most significant updates is the introduction of the Rolling Review. This approach radically transforms the data submission process: manufacturers will be able to submit sections of their technical documentation as soon as they are completed. Notified Bodies will then have the authority to begin the assessment step-by-step, without having to wait for the full dossier. It is a paradigm shift that promises to significantly streamline certification timelines.
OUTLOOK AND LEGISLATIVE PROCESS
Although the filed text is an official document, it is essential to maintain a cautious perspective: we are still in the proposal stage. The document will now be subject to discussion and may undergo amendments during the legislative process within the European Parliament and the Council. For manufacturers in the sector, now is the time to closely monitor every update to stay prepared for the challenges of an ever-evolving market.
Your Partner in Quality, Safety, and Compliance
The life sciences sector requires specialized knowledge and reliable support. With our broad expertise, we help organizations comply with laws and regulations, ensure quality, and continue to innovate with confidence.